Tag: Research Update
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Continuing ALK NSCLC TKI Treatment while on Chemotherapy Leads to Better Outcomes
A recent multi-center study examined outcomes for ALK-positive NSCLC patients who continued their ALK TKI while receiving platinum/pemetrexed chemotherapy after disease progression. The findings suggest that maintaining targeted therapy alongside chemotherapy may improve overall survival and reduce the risk of brain progression in certain patients.